{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T18:45:16Z","timestamp":1772217916414,"version":"3.50.1"},"reference-count":44,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T00:00:00Z","timestamp":1722384000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The efficacy of PD-1 blocking agents in advanced NSCLC has shown prolonged effectiveness, but only in a minority of patients. Multiple biomarkers have been explored to predict treatment benefit, yet their combined performance remains inadequately examined. In this study, we assessed the combined predictive performance of multiple biomarkers in NSCLC patients treated with nivolumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Pretreatment samples from 135 patients receiving nivolumab were used to evaluate the predictive performance of CD8 tumor-infiltrating lymphocytes (TILs), intratumoral (IT) localization of CD8 TILs, PD-1 high expressing TILs (PD1\n                      <jats:sup>T<\/jats:sup>\n                      TILs), CD3 TILs, CD20 B-cells, tertiary lymphoid structures (TLS), PD-L1 tumor proportion score (TPS) and the Tumor Inflammation score (TIS). Patients were randomly assigned to a training (n = 55) and validation cohort (n = 80). The primary outcome measure was Disease Control at 6 months (DC 6m) and the secondary outcome measure was DC at 12 months (DC 12m).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In the validation cohort, the two best performing composite biomarkers (i.e. CD8+IT-CD8 and CD3+IT-CD8) demonstrated similar or lower sensitivity (64% and 83%) and NPV (76% and 85%) compared to individual biomarkers PD-1\n                      <jats:sup>T<\/jats:sup>\n                      TILs and TIS (sensitivity: 72% and 83%, NPV: 86% and 84%) for DC 6m, respectively. Additionally, at 12 months, both selected composite biomarkers (CD8+IT-CD8 and CD8+TIS) demonstrated inferior predictive performance compared to PD-1\n                      <jats:sup>T<\/jats:sup>\n                      TILs and TIS alone. PD-1\n                      <jats:sup>T<\/jats:sup>\n                      TILs and TIS showed high sensitivity (86% and 100%) and NPV (95% and 100%) for DC 12m. PD-1\n                      <jats:sup>T<\/jats:sup>\n                      TILs could more accurately discriminate patients with no long-term benefit, as specificity was substantially higher compared to TIS (74% versus 39%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Composite biomarkers did not show improved predictive performance compared to PD-1\n                      <jats:sup>T<\/jats:sup>\n                      TILs and TIS alone for both the 6- and 12-month endpoints. PD-1\n                      <jats:sup>T<\/jats:sup>\n                      TILs and TIS identified patients with DC 12m with high sensitivity. Patients with no long-term benefit to PD-1 blockade were most accurately identified by PD-1\n                      <jats:sup>T<\/jats:sup>\n                      TILs.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0293707","type":"journal-article","created":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T15:58:36Z","timestamp":1722441516000},"page":"e0293707","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":3,"title":["Head-to-head comparison of composite and individual biomarkers to predict clinical benefit to PD-1 blockade in non-small cell lung cancer"],"prefix":"10.1371","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4371-8904","authenticated-orcid":true,"given":"Karlijn","family":"Hummelink","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4910-4535","authenticated-orcid":true,"given":"Vincent","family":"van der Noort","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mirte","family":"Muller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7014-470X","authenticated-orcid":true,"given":"Robert D.","family":"Schouten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6372-2153","authenticated-orcid":true,"given":"Michel M.","family":"van den Heuvel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7431-2854","authenticated-orcid":true,"given":"Daniela S.","family":"Thommen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7329-6995","authenticated-orcid":true,"given":"Egbert F.","family":"Smit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerrit A.","family":"Meijer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kim","family":"Monkhorst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2024,7,31]]},"reference":[{"issue":"19","key":"pone.0293707.ref001","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus Chemotherapy for PD-L1\u2013Positive Non\u2013Small-Cell Lung Cancer","volume":"375","author":"M Reck","year":"2016","journal-title":"N Engl J Med"},{"issue":"17","key":"pone.0293707.ref002","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"H Borghaei","year":"2015","journal-title":"N Engl J Med"},{"issue":"10066","key":"pone.0293707.ref003","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"A Rittmeyer","year":"2017","journal-title":"Lancet"},{"issue":"2","key":"pone.0293707.ref004","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"J Brahmer","year":"2015","journal-title":"N Engl J Med"},{"issue":"21","key":"pone.0293707.ref005","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"EB Garon","year":"2015","journal-title":"N Engl J Med"},{"issue":"7","key":"pone.0293707.ref006","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1200\/JCO.18.00149","article-title":"Updated analysis of KEYNOTE-024: Pembrolizumab versus platinum-based chemotherapy for advanced non\u2013small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater","volume":"37","author":"M Reck","year":"2019","journal-title":"J Clin Oncol"},{"issue":"28","key":"pone.0293707.ref007","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1200\/JCO.19.00934","article-title":"Five-year overall survival for patients with advanced non-small-cell lung cancer treated with pembrolizumab: Results from the phase i KEYNOTE-001 study","volume":"37","author":"EB Garon","year":"2019","journal-title":"J Clin Oncol"},{"issue":"6","key":"pone.0293707.ref008","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1093\/annonc\/mdz109","article-title":"How to make the best use of immunotherapy as first-line treatment of advanced\/metastatic non-small-cell lung cancer","volume":"30","author":"S Peters","year":"2019","journal-title":"Ann Oncol"},{"issue":"1","key":"pone.0293707.ref009","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/annonc\/mdv489","article-title":"Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: A potential issue for anti-PD-L1 therapeutic strategies","volume":"27","author":"M Ilie","year":"2016","journal-title":"Ann Oncol"},{"issue":"4","key":"pone.0293707.ref010","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/modpathol.2016.213","article-title":"Heterogeneous expression of PD-L1 in pulmonary squamous cell carcinoma and adenocarcinoma: Implications for assessment by small biopsy","volume":"30","author":"TJ Gniadek","year":"2017","journal-title":"Mod Pathol"},{"issue":"8","key":"pone.0293707.ref011","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1016\/j.jtho.2019.04.025","article-title":"Impact of Patient Characteristics, Prior Therapy, and Sample Type on Tumor Cell Programmed Cell Death Ligand 1 Expression in Patients with Advanced NSCLC Screened for the ATLANTIC Study","volume":"14","author":"AM Boothman","year":"2019","journal-title":"J Thorac Oncol"},{"issue":"9","key":"pone.0293707.ref012","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.jtho.2020.04.026","article-title":"Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC","volume":"15","author":"L Hong","year":"2020","journal-title":"J Thorac Oncol"},{"issue":"1","key":"pone.0293707.ref013","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1001\/jamaoncol.2015.3638","article-title":"Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung cancer","volume":"2","author":"J McLaughlin","year":"2016","journal-title":"JAMA Oncol"},{"issue":"7","key":"pone.0293707.ref014","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1136\/jclinpath-2019-205993","article-title":"Multicentre study on the consistency of PD-L1 immunohistochemistry as predictive test for immunotherapy in non-small cell lung cancer","volume":"73","author":"R Butter","year":"2020","journal-title":"J Clin Pathol"},{"issue":"6230","key":"pone.0293707.ref015","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"NA Rizvi","year":"2015","journal-title":"Science (80-)"},{"issue":"12","key":"pone.0293707.ref016","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1200\/JCO.18.01042","article-title":"First-line nivolumab plus ipilimumab in advanced non-small-cell lung cancer (CheckMate 568): Outcomes by programmed death ligand 1 and tumor mutational burden as biomarkers","volume":"37","author":"N Ready","year":"2019","journal-title":"J Clin Oncol"},{"issue":"9","key":"pone.0293707.ref017","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/j.jtho.2020.05.019","article-title":"The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee","volume":"15","author":"LM Sholl","year":"2020","journal-title":"J Thorac Oncol"},{"issue":"7528","key":"pone.0293707.ref018","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"PC Tumeh","year":"2014","journal-title":"Nature"},{"issue":"4","key":"pone.0293707.ref019","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41568-019-0235-4","article-title":"CD8+ T cell states in human cancer: insights from single-cell analysis","volume":"20","author":"AM van der Leun","year":"2020","journal-title":"Nat Rev Cancer"},{"issue":"7652","key":"pone.0293707.ref020","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/nature22079","article-title":"T-cell invigoration to tumour burden ratio associated with anti-PD-1 response","volume":"545","author":"AC Huang","year":"2017","journal-title":"Nature"},{"issue":"26","key":"pone.0293707.ref021","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 Blockade in Tumors with Mismatch-Repair Deficiency","volume":"372","author":"DT Le","year":"2015","journal-title":"N Engl J Med"},{"issue":"8","key":"pone.0293707.ref022","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1038\/s41416-018-0220-9","article-title":"Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy","volume":"119","author":"JD Fumet","year":"2018","journal-title":"Br J Cancer"},{"issue":"16","key":"pone.0293707.ref023","doi-asserted-by":"crossref","first-page":"5061","DOI":"10.1158\/1078-0432.CCR-18-4275","article-title":"Tumor characteristics associated with benefit from pembrolizumab in advanced non\u2013small cell lung cancer","volume":"25","author":"S Hu-Lieskovan","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"7","key":"pone.0293707.ref024","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-018-0057-z","article-title":"A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with pd-1 blockade","volume":"24","author":"DS Thommen","year":"2018","journal-title":"Nat Med"},{"issue":"10","key":"pone.0293707.ref025","first-page":"1","article-title":"PD-1T TILs as a predictive biomarker for clinical benefit to PD-1 blockade in patients with advanced NSCLC","author":"K Hummelink","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"February","key":"pone.0293707.ref026","article-title":"Tertiary lymphoid structures improve immunotherapy and survival in melanoma","author":"R Cabrita","year":"2020","journal-title":"Nature"},{"issue":"February","key":"pone.0293707.ref027","article-title":"B cells and tertiary lymphoid structures promote immunotherapy response","author":"BA Helmink","year":"2020","journal-title":"Nature"},{"issue":"June 2018","key":"pone.0293707.ref028","article-title":"B cells are associated with survival and immunotherapy response in sarcoma","volume":"577","author":"F Petitprez","year":"2020","journal-title":"Nature"},{"issue":"8","key":"pone.0293707.ref029","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1172\/JCI91190","article-title":"blockade IFN- \u03b3 \u2013related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"M Ayers","year":"2017","journal-title":"J Clin Invest"},{"issue":"10030","key":"pone.0293707.ref030","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/S0140-6736(16)00587-0","article-title":"Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): A multicentre, open-label, phase 2 randomised controlled trial","volume":"387","author":"L Fehrenbacher","year":"2016","journal-title":"Lancet"},{"issue":"16","key":"pone.0293707.ref031","doi-asserted-by":"crossref","first-page":"3857","DOI":"10.1158\/1078-0432.CCR-17-3451","article-title":"Interferon gamma messenger RNA Signature in tumor biopsies predicts outcomes in patients with non\u2013small cell lung carcinoma or urothelial cancer treated with durvalumab","volume":"24","author":"BW Higgs","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"7","key":"pone.0293707.ref032","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1200\/JCO.2017.75.3384","article-title":"Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing","volume":"36","author":"H Rizvi","year":"2018","journal-title":"J Clin Oncol"},{"issue":"5","key":"pone.0293707.ref033","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.ccell.2018.03.018","article-title":"Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer","volume":"33","author":"MD Hellmann","year":"2018","journal-title":"Cancer Cell"},{"issue":"1","key":"pone.0293707.ref034","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40425-019-0589-x","article-title":"Automated image analysis of NSCLC biopsies to predict response to anti-PD-L1 therapy","volume":"7","author":"S Althammer","year":"2019","journal-title":"J Immunother Cancer"},{"key":"pone.0293707.ref035","article-title":"A dysfunctional T cell gene signature for predicting non-response to PD-1 blockade in non-small cell lung cancer that is suitable for routine clinical diagnostics","author":"K Hummelink","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"1","key":"pone.0293707.ref036","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40425-018-0367-1","article-title":"Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): Results from The Cancer Genome Atlas (TCGA)","volume":"6","author":"P Danaher","year":"2018","journal-title":"J Immunother Cancer"},{"issue":"1","key":"pone.0293707.ref037","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41591-018-0266-5","article-title":"Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers","volume":"25","author":"W Scheper","year":"2019","journal-title":"Nat Med"},{"issue":"7706","key":"pone.0293707.ref038","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/s41586-018-0130-2","article-title":"Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates","volume":"557","author":"Y Simoni","year":"2018","journal-title":"Nature"},{"issue":"7870","key":"pone.0293707.ref039","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41586-021-03704-y","article-title":"Phenotype, specificity and avidity of antitumour CD8+ T cells in melanoma","volume":"596","author":"G Oliveira","year":"2021","journal-title":"Nature"},{"key":"pone.0293707.ref040","first-page":"126","volume-title":"Nature","author":"JX Caushi","year":"2021"},{"issue":"February","key":"pone.0293707.ref041","first-page":"eabl5447","article-title":"Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers","volume":"884","author":"FJ Lowery","year":"2022","journal-title":"Science"},{"issue":"2","key":"pone.0293707.ref042","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1158\/2326-6066.CIR-16-0391","article-title":"Temporally distinct PD-L1 expression by tumor and host cells contributes to immune escape","volume":"5","author":"T Noguchi","year":"2017","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"pone.0293707.ref043","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12967-019-2100-3","article-title":"The tumor inflammation signature (TIS) is associated with anti-PD-1 treatment benefit in the CERTIM pan-cancer cohort","volume":"17","author":"D Damotte","year":"2019","journal-title":"J Transl Med"},{"issue":"2","key":"pone.0293707.ref044","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1158\/2326-6066.CIR-13-0216","article-title":"CD4 T-cell subsets and tumor immunity: the helpful and the not-so-helpful","volume":"2","author":"HJ Kim","year":"2014","journal-title":"Cancer Immunol Res"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0293707","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T15:59:09Z","timestamp":1722441549000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0293707"}},"subtitle":[],"editor":[{"given":"Ming-Ching","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2024,7,31]]},"references-count":44,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7,31]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0293707","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2023.10.19.23297261","asserted-by":"object"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,31]]}}}